As the only national pilot city for the comprehensive value evaluation of real-world medical insurance in the three northeastern provinces, our city has completed multiple phased tasks. All work continues to advance in depth and has achieved positive progress. Recently, the First Affiliated Hospital of Dalian Medical University and the Second Affiliated Hospital of Dalian Medical University have successfully been selected as national credible evaluation point hospitals for the comprehensive value evaluation of real-world medical insurance, and they are the only two shortlisted institutions in Liaoning Province.

Real-world medical insurance evaluation refers to the assessment of the safety, effectiveness, economy, fairness, and appropriateness of drugs, consumables, etc. in real patients and real environments through the data generated by daily hospital diagnoses and treatments, providing more clinically relevant scientific evidence for decisions such as the adjustment of the medical insurance catalog, price negotiations, renewal of national negotiation agreements, and centralized procurement.

Since the National Healthcare Security Administration deployed the pilot work in September 2025, the Dalian municipal government and medical insurance departments have attached great importance to it. They have strictly met the national requirements, closely combined with local realities, and steadily completed key tasks such as preliminary research and preparation, determination of core entities, and construction of the data security guarantee system. By formulating a three-phase pilot plan, clarifying ten evaluation processes, designating two hospitals as credible evaluation points, and relying on the leading role of the Medical Insurance Research Association, a collaborative working pattern involving the government, enterprises, and research institutions has been established. Currently, the pilot has successfully launched its first project recruitment, attracting many pharmaceutical companies to participate, laying a solid foundation for subsequent work.

Next, Dalian will closely focus on the core tasks of the pilot, actively promote project recruitment and the formulation of the "early collection list", continuously deepen the collaborative mechanism among the government, enterprises, and research institutions, and strictly implement quality control at each stage. Focusing on key areas such as the evaluation of innovative drugs in the medical insurance catalog and the substitution of generic drugs, Dalian will strive to explore and form a replicable and promotable "Dalian practice".